Ganaxolone: Phase II data

An open-label, U.S. and Italian Phase II trial showed that 5 of 8 PCDH19 female pediatric epilepsy patients ages 2-18 who received once-daily oral ganaxolone for up to 26 weeks achieved a >50% reducti...